Literature DB >> 17437396

Amoebiasis: current status in Australia.

Sebastiaan J van Hal1, Damien J Stark, Rashmi Fotedar, Debbie Marriott, John T Ellis, Jock L Harkness.   

Abstract

Entamoeba histolytica is one of the most common parasitic infections worldwide, infecting about 50 million people and resulting in 40,000-100,000 deaths a year. In Australia, people at risk of infection include immigrants, travellers returning from countries of high endemicity, Indigenous people, and men who have sex with men. Clinical manifestations range from asymptomatic carriage to invasive disease. Amoebic colitis and amoebic liver abscess are the most common invasive manifestations observed in Australia. Diagnosis depends on a high index of suspicion and laboratory investigations. Molecular methods (using the polymerase chain reaction) are the most sensitive for identifying and differentiating Entamoeba species. Treatment should always include a luminal agent to eradicate colonisation, prevent spread and/or reduce the risk of invasive disease. Medical therapy can successfully cure invasive disease, including amoebic liver abscesses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437396     DOI: 10.5694/j.1326-5377.2007.tb00975.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  26 in total

1.  Colocutaneous fistula secondary to amoebiasis.

Authors:  Owain P Jones; John A Murphy; Bushra N Hamid; Dale Vimalachandran
Journal:  Int J Surg Case Rep       Date:  2010-12-21

2.  Evaluation of multiplex tandem real-time PCR for detection of Cryptosporidium spp., Dientamoeba fragilis, Entamoeba histolytica, and Giardia intestinalis in clinical stool samples.

Authors:  D Stark; S E Al-Qassab; J L N Barratt; K Stanley; T Roberts; D Marriott; J Harkness; J T Ellis
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

3.  Case Report: Endemic Amebiasis in Australia: Implications for Residents, Travelers, and Clinicians.

Authors:  Simon Smith; Gael E Phillips; William J H McBride; Josh Hanson
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

4.  Intestinal parasites of children and adults in a remote Aboriginal community of the Northern Territory, Australia, 1994-1996.

Authors:  Jennifer Shield; Kieran Aland; Thérèse Kearns; Glenda Gongdjalk; Deborah Holt; Bart Currie; Paul Prociv
Journal:  Western Pac Surveill Response J       Date:  2015-03-06

5.  Seroprevalence of Entamoeba histolytica infection among men who have sex with men in Sydney, Australia.

Authors:  Rodney James; Joel Barratt; Deborah Marriott; John Harkness; Damien Stark
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

6.  Seroprevalence of Entamoeba histolytica infection in China.

Authors:  Bin Yang; Yingdan Chen; Liang Wu; Longqi Xu; Hiroshi Tachibana; Xunjia Cheng
Journal:  Am J Trop Med Hyg       Date:  2012-07       Impact factor: 2.345

7.  Comparison of stool antigen detection kits to PCR for diagnosis of amebiasis.

Authors:  D Stark; S van Hal; R Fotedar; A Butcher; D Marriott; J Ellis; J Harkness
Journal:  J Clin Microbiol       Date:  2008-03-26       Impact factor: 5.948

Review 8.  Clinical significance of enteric protozoa in the immunosuppressed human population.

Authors:  D Stark; J L N Barratt; S van Hal; D Marriott; J Harkness; J T Ellis
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

9.  Prognostic indications of the failure to treat amoebic liver abscesses.

Authors:  Martín Sánchez-Aguilar; Onofre Morán-Mendoza; Miguel F Herrera-Hernández; Juan Francisco Hernández-Sierra; Peter B Mandeville; J Humberto Tapia-Pérez; Martín Sánchez-Reyna; José Juan Sánchez-Rodríguez; Antonio Gordillo-Moscoso
Journal:  Pathog Glob Health       Date:  2012-08       Impact factor: 2.894

Review 10.  Update on laboratory diagnosis of amoebiasis.

Authors:  Syazwan Saidin; Nurulhasanah Othman; Rahmah Noordin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-25       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.